Mapi Pharma Initiates Phase I/II Trial for Once-Monthly Cariprazine Depot Injection
核心洞察
Mapi Pharma (搜索) has enrolled the first patient in a Phase I/II study evaluating its once-monthly injectable cariprazine formulation for schizophrenia (搜索) and bipolar disorder (搜索) treatment.
The depot formulation addresses physician preference for long-acting antipsychotics and aims to improve patient compliance while reducing relapse risk compared to daily oral dosing.
The multinational trial is funded by an undisclosed pharmaceutical partner with a "Go-no-Go option" for advancing to Phase III development.
Mapi Pharma (搜索) Ltd. has achieved a significant milestone in its clinical development program by enrolling the first patient in a Phase I/II study evaluating its once-monthly injectable cariprazine formulation. The Israel-based biopharmaceutical company announced the advancement of its depot antipsychotic treatment designed for patients with schizophrenia (搜索) and bipolar disorder (搜索).
Addressing Treatment Compliance Challenges
The injectable cariprazine formulation, developed using Mapi's patented depot technology, demonstrates a long-acting release profile suitable for monthly administration. This approach directly addresses a critical gap in current treatment options, as physicians generally prefer long-acting formulations for schizophrenia (搜索) and bipolar disorder (搜索) management, while existing cariprazine products require daily oral dosing.
"This is the first clinical study we are initiating as part of a series of depot products Mapi is developing," said Ehud Marom, Chairman and Chief Executive Officer of Mapi Pharma (搜索). "We believe that, if approved, our once-monthly injectable Cariprazine could provide a valuable new treatment option for patients with schizophrenia (搜索) and bipolar disorder (搜索), with the potential to improve long term outcomes."
Clinical Development Strategy
The multinational Phase I/II trial is designed to evaluate dosing, safety, and efficacy parameters. Initial recruitment is taking place in Israel, with plans to expand to additional international centers. The study represents a strategic approach to improving treatment paradigms by potentially achieving better patient compliance, reducing relapse risk, and simplifying disease management for both patients and healthcare providers.
Mapi has established dedicated production facilities specifically for the cariprazine depot formulation, indicating the company's commitment to advancing this therapeutic approach through clinical development and potential commercialization.
Partnership and Intellectual Property
The clinical trial is being funded through an upfront payment from an undisclosed large pharmaceutical company, following a recent development agreement between the parties. The partnership structure includes a "Go-no-Go option" that allows the pharmaceutical partner to advance the product into Phase III development as part of ongoing negotiations for a definitive commercial agreement.
Mapi's intellectual property portfolio for depot cariprazine formulations encompasses dosing regimens ranging from once weekly to every six months, providing flexibility for various treatment approaches and patient needs.
Broader Pipeline Context
This cariprazine depot study marks the beginning of Mapi's clinical evaluation of multiple depot products in development. The company's broader portfolio includes treatments for various therapeutic areas, with the depot technology platform serving as a foundation for addressing unmet medical needs across multiple indications where long-acting formulations could provide clinical advantages over existing treatment options.